Dr. Reddy's Slides 2%+ for Second Day on Semaglutide Supply Disruption Fears

Sustained selling pressure signals institutional concern over Dr. Reddy's GLP-1 pipeline as semaglutide supply chain issues threaten a high-growth revenue opportunity in diabetes and obesity markets.

ndtv-profit-business · 7/10/2026, 7:03:03 AM · Ask about this →